Quantum Genomics S.A. (2QG)

Overview

Quantum Genomics Société Anonyme is a pioneering biopharmaceutical entity concentrated on the discovery and development of novel therapeutics for cardiovascular diseases. Established in 2005, with its headquarters firmly stationed in Paris, France, the company is at the forefront of biomedical research in cardiovascular health. Leveraging its profound scientific knowledge, Quantum Genomics bases its drug development on the innovative brain inhibition mechanism targeting Aminopeptidase A, encapsulated in its BAPAI (Brain Aminopeptidase A Inhibition) technology platform. This strategic approach is primarily directed at creating efficacious treatments for high blood pressure and heart failure, addressing significant unmet medical needs within these domains.

Products and Services

Quantum Genomics Société Anonyme is engaged in the development of several groundbreaking products and services aimed at transforming cardiovascular healthcare:

• Firibastat for High Blood Pressure:

  One of the leading candidates in their pipeline, firibastat, manifests as a novel approach to treating high blood pressure. Distinguished from traditional antihypertensives, firibastat operates on the brain's mechanisms to regulate blood pressure fundamentally. The drug is in development for use both as a standalone treatment and potentially in combination with other antihypertensive therapies, providing a new cornerstone in hypertension management.

• Triple-action Therapeutic Platform (BAPAI):

  At the heart of Quantum Genomics’ research is its BAPAI technology, a triple-action therapeutic platform. This innovative approach targets the aminopeptidase A enzyme in the brain, which plays a critical role in blood pressure regulation. The technology facilitates the development of other potential treatments for cardiovascular diseases, including heart failure. Through BAPAI, the company endeavors to carve new pathways in the prevention and treatment of these conditions.